Menu
GeneBe

SPART

spartin

Basic information

Region (hg38): 13:36301637-36370180

Previous symbols: [ "SPG20" ]

Links

ENSG00000133104NCBI:23111OMIM:607111HGNC:18514Uniprot:Q8N0X7AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • Troyer syndrome (Supportive), mode of inheritance: AR
  • Troyer syndrome (Definitive), mode of inheritance: AR

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Spastic paraplegia 20, autosomal recessive (Troyer syndrome)ARGeneralGenetic knowledge may be beneficial related to issues such as selection of optimal supportive care, informed medical decision-making, prognostic considerations, and avoidance of unnecessary testingCraniofacial; Musculoskeletal; Neurologic6022528; 12134148; 18413476; 20437587; 26003402

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the SPART gene.

  • not provided (222 variants)
  • Troyer syndrome (100 variants)
  • Hereditary spastic paraplegia (18 variants)
  • not specified (8 variants)
  • Inborn genetic diseases (8 variants)
  • Neurodevelopmental delay (3 variants)
  • SPART-related condition (2 variants)
  • 6 conditions (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the SPART gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
5
clinvar
49
clinvar
1
clinvar
55
missense
118
clinvar
4
clinvar
122
nonsense
3
clinvar
2
clinvar
5
start loss
0
frameshift
8
clinvar
5
clinvar
2
clinvar
15
inframe indel
2
clinvar
2
splice donor/acceptor (+/-2bp)
1
clinvar
1
splice region
2
2
non coding
44
clinvar
31
clinvar
11
clinvar
86
Total 11 7 172 84 12

Highest pathogenic variant AF is 0.0000394

Variants in SPART

This is a list of pathogenic ClinVar variants found in the SPART region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
13-36301648-G-T Troyer syndrome Uncertain significance (Jan 13, 2018)883951
13-36301909-A-G Troyer syndrome Uncertain significance (Jan 13, 2018)883952
13-36301911-T-A Troyer syndrome Uncertain significance (Jan 12, 2018)311736
13-36302022-A-G Troyer syndrome Likely benign (Apr 27, 2017)311737
13-36302066-A-G Troyer syndrome Uncertain significance (Jan 12, 2018)311738
13-36302085-A-G Troyer syndrome Uncertain significance (Jan 13, 2018)880662
13-36302109-C-T Troyer syndrome Uncertain significance (Jan 13, 2018)311739
13-36302161-G-A Troyer syndrome Uncertain significance (Jan 13, 2018)311740
13-36302210-ATACCT-A Troyer syndrome Uncertain significance (Jun 14, 2016)311741
13-36302234-TTATC-T Troyer syndrome Likely benign (Jun 14, 2016)311742
13-36302242-A-G Troyer syndrome Benign (Jan 13, 2018)311743
13-36302294-A-G Troyer syndrome Uncertain significance (Jan 12, 2018)880663
13-36302312-G-A Troyer syndrome Uncertain significance (Jan 12, 2018)882071
13-36302330-A-G Troyer syndrome Uncertain significance (Jan 12, 2018)882072
13-36302342-A-T Troyer syndrome Uncertain significance (Jan 12, 2018)882073
13-36302457-T-C Troyer syndrome Uncertain significance (Jan 13, 2018)882074
13-36302473-C-T Troyer syndrome Uncertain significance (Jan 12, 2018)311744
13-36302517-T-G Troyer syndrome Uncertain significance (Jan 13, 2018)311745
13-36302518-C-G Troyer syndrome Uncertain significance (Jan 12, 2018)882075
13-36302566-C-T Troyer syndrome Likely benign (Apr 27, 2017)311746
13-36302571-T-C Troyer syndrome Uncertain significance (Jan 12, 2018)311747
13-36302614-T-A Troyer syndrome Uncertain significance (Jan 13, 2018)883219
13-36302679-C-T Troyer syndrome Uncertain significance (Jan 13, 2018)883220
13-36302720-G-A Troyer syndrome Uncertain significance (Jan 15, 2018)883221
13-36302741-G-A Troyer syndrome Uncertain significance (Jan 12, 2018)883222

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
SPARTprotein_codingprotein_codingENST00000451493 868543
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
2.97e-70.9831256870611257480.000243
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense0.06993463500.9890.00001814325
Missense in Polyphen8487.1170.964231055
Synonymous0.01281301300.9990.000007191320
Loss of Function2.221527.50.5450.00000132355

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.0005970.000597
Ashkenazi Jewish0.00009930.0000992
East Asian0.0002720.000272
Finnish0.00004620.0000462
European (Non-Finnish)0.0002290.000229
Middle Eastern0.0002720.000272
South Asian0.0003590.000359
Other0.0003260.000326

dbNSFP

Source: dbNSFP

Function
FUNCTION: May be implicated in endosomal trafficking, or microtubule dynamics, or both. Participates in cytokinesis (PubMed:20719964). {ECO:0000269|PubMed:20719964}.;
Disease
DISEASE: Spastic paraplegia 20, autosomal recessive (SPG20) [MIM:275900]: A form of spastic paraplegia, a neurodegenerative disorder characterized by a slow, gradual, progressive weakness and spasticity of the lower limbs. Rate of progression and the severity of symptoms are quite variable. Initial symptoms may include difficulty with balance, weakness and stiffness in the legs, muscle spasms, and dragging the toes when walking. In some forms of the disorder, bladder symptoms (such as incontinence) may appear, or the weakness and stiffness may spread to other parts of the body. SPG20 is characterized by dysarthria, distal amyotrophy, mild developmental delay and short stature. {ECO:0000269|PubMed:12134148, ECO:0000269|PubMed:27539578, ECO:0000269|PubMed:28875386}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Pathway
Endocytosis - Homo sapiens (human);EGFR1 (Consensus)

Recessive Scores

pRec
0.108

Intolerance Scores

loftool
rvis_EVS
-0.49
rvis_percentile_EVS
22.7

Haploinsufficiency Scores

pHI
0.167
hipred
Y
hipred_score
0.752
ghis
0.591

Essentials

essential_gene_CRISPR
essential_gene_CRISPR2
essential_gene_gene_trap
N
gene_indispensability_pred
gene_indispensability_score

Mouse Genome Informatics

Gene name
Spg20
Phenotype
cellular phenotype; homeostasis/metabolism phenotype; adipose tissue phenotype (the observable morphological and physiological characteristics of mammalian fat tissue that are manifested through development and lifespan); growth/size/body region phenotype; skeleton phenotype; nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); neoplasm; cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan);

Gene ontology

Biological process
abscission;negative regulation of BMP signaling pathway;lipid droplet organization;negative regulation of collateral sprouting in absence of injury;neuromuscular process;cell division;regulation of mitochondrial membrane potential;adipose tissue development
Cellular component
cytoplasm;mitochondrial outer membrane;lipid droplet;cytosol;plasma membrane;midbody;synapse
Molecular function
protein binding;ubiquitin protein ligase binding